p73-dependent apoptosis through death receptor: Impairment by human cytomegalovirus infection

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2787-2794

  Terrasson, Jérôme ^a   Allart, Sophie ^a   Martin, Hélène ^a   Lulé, Jacqueline ^a   Haddada, Hedi ^b   Caput, Daniel ^c   Davrinche, Christian ^a,d  

^a CHU PURPAN   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SANOFI   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CISPLATIN; DEATH RECEPTOR; PROTEIN P53; PROTEIN P73;

ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL SURFACE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG SENSITIVITY; EMBRYO DEVELOPMENT; HOST CELL; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; NERVE CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD95; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CASPASES; CELL LINE, TUMOR; CISPLATIN; CYTOMEGALOVIRUS INFECTIONS; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENES, TUMOR SUPPRESSOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONS; NUCLEAR PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 16844378815     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2019     Document Type: Article

References (31)

1. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001;85:1813-23.
2. Zhu K, Wang J, Zhu J, et al. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene 1999;18:7740-7.
3. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
4. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with trans-activating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
5. Yang A, Walker N, Bronson R, et al. p73-Deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
6. Yang A, Kaghad M, Caput DMcKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002;18:90-5.
7. Sheikh MS, Burns TF, Huang Y, et al. p53-Dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res 1998;58:1593-8.
8. Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998;58:5061-5.
9. Lee CW, La Thangue NB. Promoter specificity and stability control of the p53-related protein p73. Oncogene 1999;18:4171-81.
10. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-9.
11. Allart S, Martin H, Detraves C, et al. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of δN-p73α. J Biol Chem 2002;277:29063-8.
12. Goldmacher VS, Bartle LM, Skaletskaya A, et al. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci U S A 1999;96:12536-41.
13. Skaletskaya A, Bartle LM, Chittenden T, et al. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A 2001;98:7829-34.
14. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002;2:831-44.
15. Tan JT, Whitmire JK, Murali-Krishna K, et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 2000;164:2320-5.
16. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-9.
17. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
18. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066-75.
19. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998;16:533-40.
20. Koo MS, Kwo YG, Park JH, et al. Signaling and function of caspase and c-jun N-terminal kinase in cisplatin-induced apoptosis. Mol Cells 2002;13:194-201.
21. Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000;60:3947-56.
22. Kinoshita H, Yoshikawa H, Shiiki K, et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000;88:986-91.
23. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 2001;276:20633-40.
24. Casciano I, Mazzocco K, Boni L, et al. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002;9:246-51.
25. Douc-Rasy S, Barrois M, Echeynne M, et al. ΔN-p73α accumulates in human neuroblastic tumors. Am J Pathol 2002;160:631-9.
26. Scaffidi C, Schmitz I, Zha J, et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 1999;274:22532-8.
27. Raoul C, Pettmann B, Henderson CE. Active killing of neurons during development and following stress: a role for p75(NTR) and Fas? Curr Opin Neurobiol 2000;10:111-7.
28. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999;190:1033-8.
29. Zaika AI, Slade N, Erster SH, et al. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-80.
30. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62:3347-50.
31. Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002;360:1557-63.